Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Mavacamten

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 54,164Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Camzyos, 1642288-47-8, Mavacamten [inn], Mavacamten [usan], Mavacamten [who-dd], Myk-461
    Molecular Formula
    C15H19N3O2
    Molecular Weight
    273.33  g/mol
    InChI Key
    RLCLASQCAPXVLM-NSHDSACASA-N
    FDA UNII
    QX45B99R3J
    Mavacamten is under investigation in clinical trial NCT03442764 (A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
    2.1.2 InChI
    InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
    2.1.3 InChI Key
    RLCLASQCAPXVLM-NSHDSACASA-N
    2.1.4 Canonical SMILES
    CC(C)N1C(=O)C=C(NC1=O)NC(C)C2=CC=CC=C2
    2.1.5 Isomeric SMILES
    C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C
    2.2 Other Identifiers
    2.2.1 UNII
    QX45B99R3J
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Myk-461

    2.3.2 Depositor-Supplied Synonyms

    1. Camzyos

    2. 1642288-47-8

    3. Mavacamten [inn]

    4. Mavacamten [usan]

    5. Mavacamten [who-dd]

    6. Myk-461

    7. 6-[[(1s)-1-phenylethyl]amino]-3-propan-2-yl-1h-pyrimidine-2,4-dione

    8. Qx45b99r3j

    9. Sar-439152

    10. (s)-3-isopropyl-6-((1-phenylethyl)amino)pyrimidine-2,4(1h,3h)-dione

    11. Sar439152

    12. 2,4(1h,3h)-pyrimidinedione, 3-(1-methylethyl)-6-(((1s)-1-phenylethyl)amino)-

    13. 2,4(1h,3h)-pyrimidinedione, 3-(1-methylethyl)-6-[[(1s)-1-phenylethyl]amino]-

    14. Mavacamten (myk-461)

    15. Unii-qx45b99r3j

    16. Myk461

    17. Chembl4297517

    18. Schembl16320785

    19. Gtpl11265

    20. Ex-a2072

    21. Bdbm50575174

    22. S8861

    23. Who 10492

    24. Db14921

    25. Myk-461; Mavacamten; Sar439152

    26. Sar-439152; Myk-461

    27. Hy-109037

    28. Cs-0031211

    29. E83742

    30. (s)-3-isopropyl-6-((1-phenylethyl)amino) Pyrimidine-2,4(1h,3h)-dione

    31. (s)-3-isopropyl-6-((1-phenylethyl)amino)pyrimidine-2, 4(1h,3h)-dione

    32. (s)-3-isopropyl-6-(1-phenylethylamino)pyrimidine-2,4(1h,3h)-dione

    33. 3-(1-methylethyl)-6-[[(1s)-1-phenylethyl]amino]-2,4(1h,3h)-pyrimidinedione

    34. 6-(((1s)-1-phenylethyl)amino)-3-(propan-2-yl)-1,2,3,4 Tetrahydropyrimidine-2,4-dione

    35. 6-{[(1s)-1-phenylethyl]amino}-3-(propan-2-yl)pyrimidine-2,4(1h,3h)-dione

    2.4 Create Date
    2016-02-23
    3 Chemical and Physical Properties
    Molecular Weight 273.33 g/mol
    Molecular Formula C15H19N3O2
    XLogP32.1
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count4
    Exact Mass273.147726857 g/mol
    Monoisotopic Mass273.147726857 g/mol
    Topological Polar Surface Area61.4 Ų
    Heavy Atom Count20
    Formal Charge0
    Complexity411
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of hypertrophic cardiomyopathy